Literature DB >> 18452568

Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases.

Arie Perry1, C Ryan Miller, Meena Gujrati, Bernd W Scheithauer, Sandro Casavilca Zambrano, Sarah C Jost, Ravi Raghavan, Jiang Qian, Elizabeth J Cochran, Jason T Huse, Eric C Holland, Peter C Burger, Marc K Rosenblum.   

Abstract

Central nervous system neoplasms with combined features of malignant glioma and primitive neuroectodermal tumor (MG-PNET) are rare, poorly characterized, and pose diagnostic as well as treatment dilemmas. We studied 53 MG-PNETs in patients from 12 to 80 years of age (median = 54 years). The PNET-like component consisted of sharply demarcated hypercellular nodules with evidence of neuronal differentiation. Anaplasia, as seen in medulloblastomas, was noted in 70%. Within the primitive element, N-myc or c-myc gene amplifications were seen in 43%. In contrast, glioma-associated alterations involved both components, 10q loss (50%) being most common. Therapy included radiation (78%), temozolomide (63%) and platinum-based chemotherapy (31%). Cerebrospinal fluid (CSF) dissemination developed in eight patients, with response to PNET-like therapy occurring in at least three. At last follow-up, 27 patients died, their median survival being 9.1 months. We conclude that the primitive component of the MG-PNET: (i) arises within a pre-existing MG, most often a secondary glioblastoma; (ii) may represent a metaplastic process or expansion of a tumor stem/progenitor cell clone; (iii) often shows histologic anaplasia and N-myc (or c-myc) amplification; (iv) has the capacity to seed the CSF; and (v) may respond to platinum-based chemotherapy regimens.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18452568     DOI: 10.1111/j.1750-3639.2008.00167.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  47 in total

1.  Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma.

Authors:  Xianyuan Song; R Andrew Allen; S Terence Dunn; Kar-Ming Fung; Peter Farmer; Shital Gandhi; Tulika Ranjan; Alexis Demopoulos; Marc Symons; Michael Schulder; Jian Yi Li
Journal:  Int J Clin Exp Pathol       Date:  2011-09-17

Review 2.  Paediatric and adult malignant glioma: close relatives or distant cousins?

Authors:  Chris Jones; Lara Perryman; Darren Hargrave
Journal:  Nat Rev Clin Oncol       Date:  2012-05-29       Impact factor: 66.675

3.  Primitive Neuroectodermal Tumor with Glioblastoma Multiforme Components in an Adult: A Collision Tumor.

Authors:  Victoria Forbes; James Vredenburgh
Journal:  Cureus       Date:  2016-01-11

4.  Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study.

Authors:  Fausto J Rodriguez; Bernd W Scheithauer; Caterina Giannini; Sandra C Bryant; Robert B Jenkins
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

5.  Clinical, radiological, histological and molecular characteristics of paediatric epithelioid glioblastoma.

Authors:  A Broniscer; R G Tatevossian; N D Sabin; P Klimo; J Dalton; R Lee; A Gajjar; D W Ellison
Journal:  Neuropathol Appl Neurobiol       Date:  2014-04       Impact factor: 8.090

6.  Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2.

Authors:  Christine E Eyler; Qiulian Wu; Kenneth Yan; Jennifer M MacSwords; Devin Chandler-Militello; Katherine L Misuraca; Justin D Lathia; Michael T Forrester; Jeongwu Lee; Jonathan S Stamler; Steven A Goldman; Markus Bredel; Roger E McLendon; Andrew E Sloan; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cell       Date:  2011-07-08       Impact factor: 41.582

7.  Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC.

Authors:  Fredrik J Swartling; Vasil Savov; Anders I Persson; Justin Chen; Christopher S Hackett; Paul A Northcott; Matthew R Grimmer; Jasmine Lau; Louis Chesler; Arie Perry; Joanna J Phillips; Michael D Taylor; William A Weiss
Journal:  Cancer Cell       Date:  2012-05-15       Impact factor: 31.743

8.  Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.

Authors:  Hiroaki Wakimoto; Gayatry Mohapatra; Ryuichi Kanai; William T Curry; Stephen Yip; Mai Nitta; Anoop P Patel; Zachary R Barnard; Anat O Stemmer-Rachamimov; David N Louis; Robert L Martuza; Samuel D Rabkin
Journal:  Neuro Oncol       Date:  2011-11-07       Impact factor: 12.300

Review 9.  Brain tumors across the age spectrum: biology, therapy, and late effects.

Authors:  Thomas E Merchant; Ian F Pollack; Jay S Loeffler
Journal:  Semin Radiat Oncol       Date:  2010-01       Impact factor: 5.934

10.  H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications?

Authors:  Marco Gessi; Gerrit H Gielen; Jennifer Hammes; Evelyn Dörner; Anja Zur Mühlen; Andreas Waha; Torsten Pietsch
Journal:  J Neurooncol       Date:  2013-01-26       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.